Members of a UK trade union working at AstraZeneca have voted to strike following cuts in pension benefits.
Members of a UK trade union working at AstraZeneca have voted to strike following cuts in pension benefits. According to a statement from UK trade union GMB, 70% of voters in a ballot supported the call for strike action. There will now be a meeting to fix dates unless AstraZeneca can “come back to the negotiating table with meaningful terms,” said GMB.
The dispute stems from AstraZeneca’s proposals to change its pension scheme for approximately 2500 employees, based mainly at the company’s Macclesfield, United Kingdom, site. In a July statement released prior to the ballot, GMB said it had more than 600 members employed at the site. The union also added that the during the past four years, it has seen huge job losses at the site as well as “radical” changes in working practices.
“AstraZeneca has in financial terms done extremely well in recent years, last year operating profit rose by a staggering 24% compared to 2008. The first quarter of this year (2010) shows further growth year on year of 11% and hence our members see no financial need for these swingeing pension cuts,” said the GMB’s July statement.
According to GMB, talks about AstraZeneca’s pension proposals were held over a 3-month period earlier this year, but the company has not moved from its original stance. GMB says it has enlisted the support of unions across Europe.
AstraZeneca has not yet released a press statement. However, an article from Reuters claims that AstraZeneca is reviewing the ballot and has said that about a third of GMB members and less than 2% of its UK employees voted in favor of the strike.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.